The data, which the company said represent the first proof of activity of an oral RNAi drug, set the stage for an investigational new drug application filing later this year.
Without specific guidance from the FDA regarding KRAS testing, drugmakers Bristol-Myers Squibb and Amgen are facing lower sales of their colorectal cancer drugs Erbitux and Vectibix, and may need to get creative in how they market their drugs to patients and doctors.
While Helicos and Rosetta Genomics rose, shares of Cepheid were hit by its forecast of lower revenues. But, overall, the GWDN Index managed to gain ground while the broader market fell.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
